

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

November 7, 2023

Jesse Shefferman President and Chief Executive Officer Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010

> Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 Filed November 3, 2023 File No. 333-275290

Dear Jesse Shefferman:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Robert W. Downes